Search results for " liver disease"

showing 10 items of 559 documents

Angiopoietin-Like Protein 8 Is a Novel Vitamin D Receptor Target Gene Involved in Nonalcoholic Fatty Liver Pathogenesis

2018

Hepatic vitamin D receptor (VDR) expression is increased in patients with nonalcoholic fatty liver (NAFL) and is required for liver steatosis in an NAFL mouse model. However, how hepatocyte VDR is involved in setting up steatosis remains unclear. The authors transduced human hepatocyte-derived cells with an adenoviral vector encoding human VDR and found that angiopoietin-like protein 8 (ANGPTL8) expression was increased upon VDR activation by vitamin D or lithocholic acid. The mRNA levels of hepatic VDR- and vitamin D-related genes [cytochrome P450 (CYP) 2R1, CYP27A1, and CYP3A4] were higher in NAFL patients compared with normal liver subjects. Noteworthy, hepatic ANGPTL8 mRNA and protein l…

AdultMale0301 basic medicinemedicine.medical_specialtyLithocholic acidPeptide HormonesFatty Acids NonesterifiedCalcitriol receptorPathology and Forensic Medicine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAngiopoietin-Like Protein 8Non-alcoholic Fatty Liver DiseaseInternal medicineCYP27A1medicineHumansInsulinCells CulturedTriglyceridesGene knockdownCYP3A4Fatty liverMiddle Agedmedicine.diseaseAngiopoietin-like Proteins030104 developmental biologymedicine.anatomical_structureEndocrinologyGene Expression RegulationchemistryCase-Control StudiesHepatocyteHepatocytesReceptors CalcitriolFemale030211 gastroenterology & hepatologySteatosisThe American Journal of Pathology
researchProduct

Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis

2020

Non-alcoholic fatty liver disease (NAFLD) is becoming the main cause of liver disease in Western countries, especially in morbidly obese patients (MOPs). The proprotein convertase subtilisin/kexin type 9 (PCSK9) has been recently studied because of its possible involvement in the pathogenesis of NAFLD, but its role, at least in MOPs, is still controversial. The aim of this study was to clarify the correlation between the circulating levels of the PCSK9 protein (cPCSK9) and its hepatic expression with the severity of liver damage in a population of MOPs with NAFLD undergoing bariatric surgery. PCSK9 mRNA was positively correlated with FASN, PPARγ and PPARα mRNAs, while no significant differe…

AdultMale0301 basic medicinemedicine.medical_specialtySettore MED/06 - Oncologia MedicaPopulationBariatric SurgeryInflammation030204 cardiovascular system & hematologySeverity of Illness IndexPathogenesisNon-alcoholic fatty liver disease (NAFLD)03 medical and health sciencesBallooning degenerationLiver disease0302 clinical medicineInternal medicinemedicineHumansMorbidly obese patients (MOPs)educationMolecular Biologyeducation.field_of_studybusiness.industryPCSK9Fatty liverCell BiologyMiddle AgedLipid Metabolismmedicine.diseaseObesity MorbidFatty LiverProprotein convertase subtilisin/kexin type 9 (PCSK9)030104 developmental biologyEndocrinologyLiverFemaleProprotein Convertase 9medicine.symptomSteatosisbusiness
researchProduct

Non-alcoholic fatty liver disease is associated with higher metabolic expenditure in overweight and obese subjects: A case-control study

2019

Non-alcoholic fatty liver disease (NAFLD) is a common condition in Western countries. However, their metabolic characteristics are poorly known even though they could be important. Therefore, the objective of this study was to measure resting metabolic parameters in overweight/obese adults with hepatic steatosis compared to controls, matched for age, sex, and obesity level. Hepatic steatosis was diagnosed with liver ultrasound. Energy metabolism was measured with indirect calorimetry: energy expenditure (REE), predicted REE, the ratio between REE and the predicted REE, and the respiratory quotient (RQ) were reported. We measured some anthropometric, body composition, and bio-humoral paramet…

AdultMale0301 basic medicinemedicine.medical_specialtyobesitylcsh:TX341-641OverweightGastroenterologyArticle03 medical and health sciences0302 clinical medicineLiver -- Diseases -- Case studiesNon-alcoholic Fatty Liver DiseaseInternal medicineNAFLDmedicineNon-alcoholic fatty liver disease -- Case studiesOverweight persons -- Case studiesHumansObesity -- Complications -- Case studiesNutrition and Dieteticsbusiness.industryFatty liverCase-control studyCalorimetry IndirectEnergy metabolismMiddle AgedOverweightAnthropometrymedicine.diseaseObesityRespiratory quotient030104 developmental biologyCase-Control StudiesCohortBody CompositionFemale030211 gastroenterology & hepatologySteatosismedicine.symptomEnergy Metabolismbusinesslcsh:Nutrition. Foods and food supplymetabolismFood Science
researchProduct

Circulating E-selectin levels in chronic hepatitis C patients with normal or elevated transaminase before and after alpha-interferon treatment

2001

E-selectin, an adhesion molecule of the selectin family, is involved in leukocyte adhesion to the endothelium and in the cellular immunological reactions. Expression of this molecule, in fact, is physiologically absent, but it becomes evident on sinusoidal lining cells during inflammatory liver disease. The aim of this study was to evaluate the behavior of E-selectin in chronic hepatitis C (CH-C) patients with persistently normal transaminase in comparison to patients with CH-C and elevated transaminase, and its changes during alpha-interferon therapy. Immunohistochemical localization of E-selectin was also performed on liver tissue specimens of both groups. Fifty-eight subjects were divide…

AdultMaleAdhesion moleculeChronic liver diseaseE-selectinImmunologyAlanine TransaminaseHepatitis C ChronicMiddle AgedImmunohistochemistryRecombinant ProteinsTreatmentLiverInterferon Type IHumansα-interferonImmunology and AllergyFemaleAspartate Aminotransferases
researchProduct

Longterm Risk of Solid Organ De Novo Malignancies After Liver Transplantation: A French National Study on 11,226 Patients

2018

IF 3.756; International audience; De novo malignancies are one of the major late complications and causes of death after liver transplantation (LT). Using extensive data from the French national Agence de la Biomédecine database, the present study aimed to quantify the risk of solid organ de novo malignancies (excluding nonmelanoma skin cancers) after LT. The incidence of de novo malignancies among all LT patients between 1993 and 2012 was compared with that of the French population, standardized on age, sex, and calendar period (standardized incidence ratio; SIR). Among the 11,226 LT patients included in the study, 1200 de novo malignancies were diagnosed (10.7%). The risk of death was app…

AdultMaleAlcoholic liver diseasemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentPopulation[SDV.CAN]Life Sciences [q-bio]/Cancer030230 surgeryLiver transplantationGastroenterologyRisk AssessmentLiver transplantation (LT)End Stage Liver Disease03 medical and health sciences0302 clinical medicinePostoperative ComplicationsRisk FactorsInternal medicineNeoplasmsmedicineHumanseducationLiver Diseases AlcoholicTransplantationeducation.field_of_studyHepatologybusiness.industryIncidence (epidemiology)IncidenceAbsolute risk reductionMiddle Agedmedicine.diseaseConfidence interval3. Good healthLiver TransplantationStandardized mortality ratioTreatment Outcome030211 gastroenterology & hepatologySurgeryFemaleFranceRisk assessmentbusinessFollow-Up Studies
researchProduct

Prevalence and genomic variability of transfusion transmitted virus in Italian cryptogenic chronic liver disease and healthy blood donors

2002

Abstract Background. Infection with transfusion transmitted virus, a new member of the Parvoviridae family, has been found in patients both with chronic and fulminant post-transfusion cryptogenic hepatitis. Aim. To evaluate the prevalence and clinical impact of transfusion transmitted virus infection in Italy. Patients and Methods. Studies were carried out on 256 patients and control subjects from three centres from Northern, Central and Southern Italy (92 nonA-nonC chronic hepatitis, 10 acute non fulminant cryptogenic hepatitis, 41 hepatitis C virus-related chronic hepatitis and 113 blood donors). Serum transfusion transmitted virus was detected by nested polymerase chain reaction using tw…

AdultMaleBlood transfusionAdolescentmedicine.medical_treatmentHepatitis C virusBlood Donorsblood transfusionmedicine.disease_causeVirusTransfusion transmitted virusLiver diseasetransfusion transmitted virusmedicinePrevalenceHumansAgedHepatitis ChronicHepatitis B virusHepatitisTorque teno virusblood transfusion; cryptogenic chronic liver disease; transfusion transmitted virusHepatologybiologybusiness.industryGastroenterologyHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseasebiology.organism_classificationVirologyDNA Virus InfectionsItalyImmunologyDNA ViralFemalebusinesscryptogenic chronic liver disease
researchProduct

Spontaneous and antibody-dependent cellular immune reactions to ethanol-altered hepatoma cells

2008

— Spontaneous cell-mediated cytotoxicity (SCMC), antibody-dependent cellular cytotoxicity (ADCC) and proliferative lymphocyte stimulation in alcoholic liver disease (ALD) were investigated. Peripheral blood lymphocytes (PBL) from eight patients with advanced ALD and nine normal controls were tested against hepatoma cells (PLC/PRF/5) as targets. Target cells were grown in either normal culture medium or medium supplemented with 1 and 5% ethanol, respectively, for 24 to 48 h. Ethanol-exposed hepatoma cells exhibited profound and characteristic morphological alterations. Ethanol preincubation, however, proved to be without effect on immune reactions. Provided that hepatoma cells are an appropr…

AdultMaleCellular immunityAlcoholic liver diseaseCarcinoma HepatocellularBiopsyBiologyLymphocyte Activationchemistry.chemical_compoundIn vivomedicineHumansCytotoxicityLiver Diseases AlcoholicCells CulturedAntibody-dependent cell-mediated cytotoxicityEthanolEthanolHepatologyLiver NeoplasmsAntibody-Dependent Cell CytotoxicityMiddle Agedmedicine.diseaseMolecular biologyCulture MediaLiverBiochemistrychemistrybiology.proteinFemaleAntibodyImmune reactionT-Lymphocytes CytotoxicLiver
researchProduct

Are hepatitis G virus and TT virus involved in cryptogenic chronic liver disease?

2002

Abstract Background . Hepatitis G virus can cause chronic infection in man but the role of this agent in chronic liver disease is poorly understood. Little is known about the relation of another newly discovered agent, the TT virus, with chronic liver disease. Aim . To investigate the rate of infection with hepatitis G virus and TT virus in patients with cryptogenic chronic liver disease. Patients . A total of 23 subjects with chronically raised alanine transaminase and a liver biopsy in whom all known causes of liver disease had been excluded, and 4D subjects with hepatitis C virus-related chronic liver disease. Methods . Evaluation of anti-hepatitis G virus by enzyme immunoassay. Hepatiti…

AdultMaleCirrhosisHepatitis Viral HumanvirusesHepatitis C virusGB virus Cmedicine.disease_causeChronic liver diseaseLiver diseasemedicineHumansHepatitis ChronicTorque teno virusHepatitis B virusHepatitisHepatologymedicine.diagnostic_testReverse Transcriptase Polymerase Chain Reactionbusiness.industryGastroenterologyAlanine TransaminaseHepatitis CFlaviviridae InfectionsMiddle Agedmedicine.diseaseVirologyDNA Virus InfectionsLiverLiver biopsyFemalebusinessDigestive and Liver Disease
researchProduct

Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis

2021

Objective Neddylation is a druggable and reversible ubiquitin-like post-translational modification upregulated in many diseases, including liver fibrosis, hepatocellular carcinoma, and more recently, non-alcoholic fatty liver disease (NAFLD). Herein, we propose to address the effects of neddylation inhibition and the underlying mechanisms in pre-clinical models of NAFLD. Methods Hepatic neddylation measured by immunohistochemical analysis and NEDD8 serum levels measured by ELISA assay were evaluated in NAFLD clinical and pre-clinical samples. The effects of neddylation inhibition by using a pharmacological small inhibitor, MLN4924, or molecular approaches were assessed in isolated mouse hep…

AdultMaleCoronavirus disease 2019 (COVID-19)AdolescentMLN4924[SDV.BC]Life Sciences [q-bio]/Cellular BiologyDiet High-Fat03 medical and health sciencesMiceYoung Adult0302 clinical medicineNon-alcoholic Fatty Liver DiseasePolitical scienceNAFLDmedia_common.cataloged_instanceAnimalsHumansEuropean unionNeddylationMolecular BiologyInternal medicineComputingMilieux_MISCELLANEOUS030304 developmental biologymedia_commonAged0303 health sciencesTOR Serine-Threonine KinasesFatty AcidsIntracellular Signaling Peptides and ProteinsCell BiologyMiddle AgedRC31-12453. Good healthMice Inbred C57BLRare tumorDisease Models AnimalDeptor; Fatty acid oxidation; MLN4924; mTOR; NAFLD; NeddylationDeptorFatty acid oxidationHepatocytesmTOR030211 gastroenterology & hepatologyChristian ministryOriginal ArticleHumanitiesSignal Transduction
researchProduct

Effects of Fractionated Plasma Separation and Adsorption on Survival in Patients With Acute-on-Chronic Liver Failure

2012

BACKGROUND & AIMS: Fractionated plasma separation and adsorption (FPSA) is an extracorporeal procedure that supports liver function by removing endogenous toxins that cause complications from acute-on-chronic liver failure (AOCLF). We performed a randomized trial to investigate survival of patients with AOCLF treated with FPSA. METHODS: Patients with AOCLF were randomly assigned to groups given a combination of FPSA and standard medical therapy (SMT) (FPSA group, n = 77) or only SMT (SMT group, n = 68). The Prometheus liver support system was used to provide 8 to 11 rounds of FPSA (minimum of 4 hours each) for 3 weeks. Primary end points were survival probabilities at days 28 and 90, irresp…

AdultMaleExtracorporeal Circulationmedicine.medical_specialtyTime FactorsCirrhosismedicine.medical_treatmentMedizinKaplan-Meier EstimateLiver transplantationRisk AssessmentGastroenterologyEnd Stage Liver DiseaseLIVER DISEASELiver diseaseSpontaneous bacterial peritonitisHepatorenal syndromeRisk FactorsInternal medicinemedicineHumansProspective StudiesDialysisProportional Hazards ModelsHepatologybusiness.industryMORTALITYGastroenterologyBilirubinTREATMENTLiver Failure AcuteMiddle Agedmedicine.diseaseEXTRACORPOREAL LIVER SUPPORTSurgeryEuropeTreatment OutcomeFemaleSorption DetoxificationSOFA scoreLiver functionORGAN FAILUREbusinessBiomarkers
researchProduct